Friday, May 15, 2026 · 8:42 AM
Department Leader
12 PIs · 14 active grants · $4.2M annual spend · operations and finance overview.
Scope:My Department
Period:FY26 YTD
Compare to:FY25 same period
Total spend
$4.21M
4.2% vs LFY
Realized savings
$487K
+22%
· 11.6% rate
At-risk grants
2 of 14
$1.04M exposure
Avg cycle time
1.8days
62% faster
Compliance
99.4%
3 exceptions cleared
Market intelligence
Lab reagent index
142.8
+4.7%
YoY · vendor list
USD / EUR
0.918
-2.1%
EU imports cheaper
Helium spot
$28.40
+8.2%
/MCF · supply tight
Freight (LTL)
118.4
-3.1%
Index · 30d
Fed funds rate
4.25%
Hold
Capital costs stable
News affecting your spend AI Curated
Supply
Helium supply tightens — Air Liquide announces 8% surcharge for Q3
Russian export disruptions and new BLM auction policy reducing global supply. Surcharge takes effect July 1 on bulk and dewar deliveries to academic customers.
Affects 3 PIs running NMR/cryostat ops
+$14.2K/yr
est. impact
FX
USD strengthens 2.1% vs EUR over 30 days — European reagent imports cheaper
Sigma-Aldrich (Merck) and Eppendorf catalogs see effective price drops on EU-manufactured items. Window for forward-buying may be brief ahead of ECB June meeting.
EU suppliers: 38% of school spend
-$8.9K
on 90-day buy
Funding
NIH modular grant cap rises 1.2% for FY27 — budget guidance refreshed
Effective Oct 1, modular budget ceiling moves from $250K to $253K direct costs. Affects 4 of your PIs preparing competing renewals this quarter.
4 PIs · pre-submission window
+$12K/yr
budget headroom
Tariffs
Section 301 tariff increase on Chinese-made lab instruments takes effect June 1
15% additional duty on HTS codes 9027 (analytical instruments) and 9032 (automatic regulating). Wellman Lab's cell sorter renewal and 2 other purchases may be affected.
3 pending purchases
+$32K
if not pre-ordered
Vendor
Sigma-Aldrich announces 4.7% price increase across antibody catalog · effective Aug 1
Increase applies to monoclonal and polyclonal antibodies, recombinant proteins. Locked-in pricing under MSA-2023-074 protected through Dec 2026 — covers 71% of your antibody spend.
29% of spend exposed
+$6.8K/yr
est. exposure
Heading to you · 14-day forecast Telepathy
Approvals, contract events, and grant moments your office should see coming · Source data →
Confidence
Type
What's coming
Est. arrival
Value
99%
Capital · rush
Wellman Lab · BD FACSAria cell sorter renewal
In your queue now · tariff deadline June 1 · agent flagged for pre-order acceleration
Decide today
tariff window
$168K
capital
›
96%
Contract
Tanaka Lab · NovaSeq Genomics 2-yr MSA
Legal cleared · 14% off list negotiated · awaiting your signature · standard terms
This week
already routed
$72K/yr
$14K saving
›
78%
Grant rush
Diaz Lab · DoD close-out invoice cluster expected
Grant ends Sep 14 · 64% underspent · historical pattern: 8–12 invoices over 4 months · several may need your sign-off
Starts May 28
12 days · onset
~$185K
staggered
›
High
Market window
USD strong window · 3 PIs have EU purchases queued
Patel, Tanaka, Wellman · combined $84K in EU-sourced reagents in draft · forward-buy saves ~$1.8K · window closes ~mid-June
By May 28
FX window
~$1.8K
savings
›
82%
Renewal
3 MSA renewals due in Q3 · review window opens Jun 1
Strand Bio, Eppendorf Scientific, ABclonal · combined annual value $312K · sourcing team prepping benchmark data
Jun 1 +
17 days
$312K/yr
renewal value
›
88%
Aging
Memorial Day weekend · 14 approvals likely to accumulate
Pre-holiday pattern · agent will pre-screen and queue for your Tue May 27 review session · 8–12 likely auto-approvable
Tue May 27
12 days · backlog
~$240K
cumulative
›
PI & grant leaderboard
Ranked by grant health · change ranking →
PI / Grant
Budget
Utilization
Burn rate
Savings
01
Patel, R. · Diabetes mechanisms
NIH · R01-DK294112 · 18 mo left
$1.84M
$612K spent
33% · matches timeline
On pace
$84.2K
15.8% rate
›
02
Okafor, J. · Single-cell sequencing
NSF · DBI-2231445 · 14 mo left
$300K
$112K spent
37% · matches timeline
On pace
$18.4K
16.4% rate
›
03
Chen, M. · Vascular biology
AHA · 23PRE-840 · 21 mo left
$185K
$42K spent
23% · slightly under
Slow start
$5.4K
12.9% rate
›
04
Wellman, S. · Cancer immunotherapyWatch
NIH · R01-CA248932 · 6 mo left
$625K
$487K spent
78% · projecting $40K over
Hot
$11.4K
11.6% rate
›
05
Singh, A. · Neurodegeneration
NIH · R21-NS199084 · 9 mo left
$275K
$148K spent
54% · slightly behind
Watch
$9.8K
14.3% rate
›
06
Diaz, L. · Pediatric oncologyWatch
DoD · W81XWH-29-1-0214 · 4 mo left
$415K
$148K spent
36% · severe underspend
Cold
$4.1K
9.2% rate
›
07
Tanaka, H. · Microbiome therapeutics
NIH · R01-AI287551 · 24 mo left
$1.42M
$284K spent
20% · on schedule
On pace
$42.8K
15.1% rate
›
Department pulse
Comparative · school vs peers vs FY25
Catalog adoption
Your school
71%
Peer avg
54%
FY25 you
63%
Of addressable spend going through catalog or punchout. +8 pts YoY drives most of your savings rate.
Invoice on-time payment
Your school
98%
Peer avg
76%
FY25 you
84%
Receipt-prompting at invoice arrival closed the gap. Early-pay discounts captured: $8.4K YTD.
Avg req-to-PO cycle
Your school
1.8d
Peer avg
6.4d
FY25 you
4.7d
Auto-fill and shortened approval paths under contract drove the gain. Lower in the AAU-R1 cohort.